WO2023073676 - GALECTIN-1 DELIVERY FOR THERAPEUTIC CONTROL OF INTESTINAL INFLAMMATION
National phase entry:
Publication Number
WO/2023/073676
Publication Date
04.05.2023
International Application No.
PCT/IB2022/060524
International Filing Date
01.11.2022
Title **
[English]
GALECTIN-1 DELIVERY FOR THERAPEUTIC CONTROL OF INTESTINAL INFLAMMATION
[French]
ADMINISTRATION DE GALECTINE-1 POUR LE CONTRÔLE THÉRAPEUTIQUE DE L'INFLAMMATION INTESTINALE
Applicants **
UNIVERSIDAD NACIONAL DE ROSARIO
FUNDACIÓN SALES
CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET)
MARIÑO, Karina Valeria
Inventors
RABINOVICH, Gabriel Adrián
BLANCATO, Victor Sebastian
TOSCANO, Marta Alicia
MAGNI, Christian
MOROSI, Luciano Gastón
Priority Data
63/274,287
01.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2289 | |
| EPO | Filing, Examination, Granting | 9773 | |
| Japan | Filing, Examination, Granting | 2024 | |
| South Korea | Filing, Examination, Granting | 1719 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,545
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the delivery of galectins useful in the control of inflammation in diseases associated with inflammatory processes, such as intestinal inflammatory diseases. More particularly, the present invention relates to the delivery of Galectin-1 (Gal1) and Gal1-variants for controlling inflammation in such diseases. More specifically, the present invention relates to the treatment of Intestinal Inflammatory Diseases, in particular ulcerative colitis (UC) and Crohn's disease (CD). Even more specifically, the present invention relates to optimized lactic-acid bacterial strains, capable of producing and secreting considerable levels of human Gal1 and Gal1 variants for delivering galectin-1 into the inflamed tissue. Also, the present invention relates to expression cassettes comprising those Gal1 and variants thereof and the vectors wherein said expression cassettes are contained.[French]
La présente invention concerne l'administration de galectines utiles dans le contrôle de l'inflammation dans des maladies associées à des processus inflammatoires, tels que des maladies inflammatoires intestinales. Plus particulièrement, la présente invention concerne l'administration de Galectine-1 (Gal1) et de variants de Gal1 pour lutter contre l'inflammation dans de telles maladies. Plus spécifiquement, la présente invention concerne le traitement de maladies inflammatoires intestinales, en particulier la rectocolite hémorragique (UC) et la maladie de Crohn (CD). Encore plus spécifiquement, la présente invention concerne des souches de bactéries lactiques optimisées, capables de produire et de sécréter des niveaux considérables de variants de Gal1 et de Gal1 humains pour administrer de la galectine-1 dans le tissu inflammatoire. La présente invention concerne également des cassettes d'expression comprenant ces Gal1 et variants associés et les vecteurs dans lesquels lesdites cassettes d'expression sont contenues.